EGFR and non-small cell lung carcinoma: Interestingly, while EGFR was recognized as a potential therapeutic target of NSCLC, its binding adaptor, growth factor receptor bound protein 2 (GRB2), was shown to be a stabilized EGFR and co-activated downstream to the MAPK/ERK pathway40.